FDA Expands Tecentriq Approval in Non-Squamous NSCLC

]]>(MedPage Today) -- The FDA on Tuesday expanded indications for atezolizumab (Tecentriq) to include its use along with chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC) in the frontline setting, Genentech announced.Based...